Pfizer Archives

mRNA DNA race Covid 19 vaccine BioNTech Pfizer

News and Trends 22 Dec 2020

EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19

BioNTech and Pfizer’s Covid-19 vaccine, made from messenger RNA, has become the first of its kind to be approved by the EMA. The EMA has granted conditional approval to Comirnaty, a vaccine against Covid-19 developed by BioNTech and Pfizer. The approval comes weeks after the UK became the first country in the world to approve […]

December 22, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 19 Nov 2020

mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine

The field of messenger RNA therapeutics is flying high as BioNTech and Pfizer conclude a phase III trial with their Covid-19 vaccine showing 95% effectiveness. The phase III trial recruited over 43,000 volunteers to gauge whether Covid-19 infections could be prevented by a vaccine made out of messenger RNA (mRNA). One group received two doses […]

November 19, 2020 - 6 minutesmins - By Jonathan Smith

News and Trends 3 Jul 2020

Pfizer-BioNTech Covid-19 Vaccine Shows Phase I Promise

A vaccine made out of messenger RNA (mRNA), developed by the US pharmaceutical giant Pfizer and its German partner BioNTech, has produced antibodies against the Covid-19 pathogen in healthy volunteers. The results come from an interim analysis of an ongoing phase I clinical trial in 45 participants. So far, all test subjects who received two […]

July 3, 2020 - 3 minutesmins - By Victor Kotsev

News and Trends 7 May 2020

Lyme Disease Vaccine Gets Pfizer’s Backing in €284M Deal

The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The deal they signed is expected to help compensate for the impact of the Covid-19 pandemic on Valneva’s financial outlook for 2020. The latest alliance will pool Valneva’s vaccine R&D expertise with Pfizer’s vast drug development […]

May 7, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

BioNTech Production scaled e1584385495951

News and Trends 29 Apr 2020

Update: BioNTech and Pfizer’s mRNA Vaccine for Covid-19 Tested in Humans

Update (29/04/2020): A vaccine developed by the German company BioNTech and its big pharma partner Pfizer has become the first European mRNA vaccine for Covid-19 to enter human testing in a phase I/II trial. Since dosing began last week, twelve volunteers in Germany have been given the vaccine. The first part of the trial — […]

April 29, 2020 - 5 minutesmins - By Helen Albert

News and Trends 8 Jan 2020

Therachon Founders Spin Out New Rare Disease Biotech With €31M Investment

The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare diseases. The spin-out comes after Therachon was acquired by Pfizer last year in a deal worth up to €700M. Therachon’s CEO, CBO, CFO and CMO will all move to the […]

January 8, 2020 - 2 minutesmins - By Helen Albert

News and Trends 4 Nov 2019

Finnish Genetics Study Provides Clues for Treating Type 2 Diabetes

A genetic mutation common to Finnish populations has been found to protect against type 2 diabetes by increasing insulin in the blood, providing a potential target for new drugs. The mutation is found in at least 0.2% of the population in western Finland, whereas it only appears in 0.02% of other European populations. The mutation […]

November 4, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2019

European Project Launches to Tailor Autoimmune Disease Treatments

Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […]

October 31, 2019 - 2 minutesmins - By Jonathan Smith

achondroplasia pfizer therachon acquisition

More News! 9 May 2019

Pfizer Pays up to €700M to Acquire Swiss Biotech Restoring Bone Growth in Achondroplasia

Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development of its drug improving bone growth in achondroplasia. This genetic condition inhibits […]

May 9, 2019 - 2 minutesmins - By Jonathan Smith

GSK ViiV Healthcare Double HIV Treatment

News and Trends 4 Apr 2019

Update: Two-Drug HIV Treatment Effective for up to Three Years

Update (04/04/2019): ViiV Healthcare’s two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in patients’ blood. In a clinical study, 513 HIV-infected people switched to daily pills of Juluca from their standard drug regimes, which included three or four different drugs. Juluca was effective at suppressing the virus for […]

April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 1 Oct 2018

Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks?

Despite more than a century of scientific endeavour, influenza remains one of the most deadly infectious diseases worldwide. Across Europe, many biotechs are working on novel solutions that could dramatically improve the protection rates offered by current vaccines. Some may even lead to the holy grail of influenza research – a universal flu vaccine. Each […]

October 1, 2018 - 8 minutesmins - By David Cox

News and Trends 16 Aug 2018

Pfizer Offers €374M for German mRNA Flu Vaccine

BioNTech, based in Mainz, Germany, has entered into a partnership with Pfizer worth up to $425M (€374M) to develop an mRNA-based flu vaccine, which could be produced much more quickly than current flu vaccines. Messenger RNA (mRNA) is one of the building blocks living organisms use to create proteins from genes. BioNTech is developing prophylactic […]

August 16, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us